Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Sep 26, 2013 7:03am
337 Views
Post# 21768818

RE:RE:RE:Duncan Middlemiss, P.Eng., New President & CEO of SAS

RE:RE:RE:Duncan Middlemiss, P.Eng., New President & CEO of SASTerry:

Thanks for the reminder on the Denver Gold Forum. You always said that the key to PPS appreciation is the new shareholders.

WD had a good delivery. He also appears to be brushing up on his mining terminalogy. However, the use of ramp (in the context of access via a decline) and ramping (in the context of increasing production)  in the same point may be a point worth thinking of.

In addition, the use of Black Fox and Grey Fox when doing comparisons could lose some. i.e. the point being the common term Fox. Of course the new targets of Wiskey Jack and Gibson, etc while in Grey Fox are dissimiliar enough to avoid confusion especially when the target audience at a presentation like the DGS can be expected to have a bit of information overload.

A possible visibility move could have been having MT & DR on stage with him as he introduced them as being in the audience. Doing so will not reduce his speaking time but make it easier for those looking to contact the company for more info. 

We talked about the distraction of the pointer before. i.e. he should have a spare and the both should be checked b4 going up on stage/podium.

BWDIK? Sometimes a very positive presentation (which WD had) can lose some traction due to delivery (e.g  use of ramps and ramping) and distraction(s) ( e.g. pointer.....which happened b4).

Cheers
Stanley



Bullboard Posts